[Graft vs. tumor effect in chronic granulocytic leukemia].
Ruiz-Argüelles
Guillermo J
GJ
Centro de Hematología y Medicina Interna, Clínica Ruiz de Puebla, Pue. gruiz1@clinicaruiz.com
D000328:Adult; D000493:Allopurinol / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000032:analysis; D019090:Case Management; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D016044:Fusion Proteins, bcr-abl / Q000032:analysis / Q000037:antagonists & inhibitors; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology; D020544:Graft vs Leukemia Effect; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D000068877:Imatinib Mesylate; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D012074:Remission Induction; D013792:Thalidomide / Q000627:therapeutic use; D019172:Transplantation Conditioning
D001549:Benzamides; D014408:Biomarkers, Tumor; D007166:Immunosuppressive Agents; D010879:Piperazines; D011743:Pyrimidines; D013792:Thalidomide; D000493:Allopurinol; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D009173:Mycophenolic Acid; D011241:Prednisone; D006918:Hydroxyurea
El efecto de injerto contra tumor en leucemia granulocítica crónica.